Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Duke University to evaluate Panzem NCD in breast cancer
July 28th, 2005
EntreMed, Inc., (ENMD), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, announced that Duke University Medical Center has received a grant from the Susan G. Komen Breast Cancer Foundation to study the company's lead compound, 2ME2 (2-Methoxyestradiol or Panzem), in metastatic breast cancer. Basic, translational, and clinical studies will be conducted using Panzem NCD in combination with a variety of chemotherapeutic agents to determine the effect of 2ME2 on chemotherapy resistant tumors. EntreMed will supply Panzem NCD for these studies. Kimberly L. Blackwell, MD,...
Source: Women's Health Weekly (2005-07-28)
|
